Erin W Meermeier,P Leif Bergsagel,Marta Chesi
Erin W Meermeier
Recent therapeutic advances have significantly improved the outcome for patients with multiple myeloma (MM). The backbone of successful standard therapy is the combination of Ikaros degraders, glucocorticoids, and proteasome inhibitors that...
Yonina R Murciano-Goroff,Manik Uppal,Monica Chen et al.
Yonina R Murciano-Goroff et al.
Large-scale tumor molecular profiling has revealed that diverse cancer histologies are driven by common pathways with unifying biomarkers that can be exploited therapeutically. Disease-agnostic basket trials have been increasingly utilized ...
Daniel A Bonsor,Dhirendra K Simanshu
Daniel A Bonsor
Mutations in RAS proteins play a pivotal role in the development of human cancers, driving persistent RAF activation and deregulating the Mitogen-Activated Protein Kinase (MAPK) signaling pathway. While progress has been made in targeting s...
Joelle P Straehla,David A Reardon,Patrick Y Wen et al.
Joelle P Straehla et al.
The blood-brain barrier is critically important for the treatment of both primary and metastatic cancers of the central nervous system (CNS). Clinical outcomes for patients with primary CNS tumors are poor and have not significantly improve...
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy [0.03%]
基于T细胞受体的细胞治疗靶向驱动癌基因及其他公共新抗原
Tijana Martinov,Philip D Greenberg
Tijana Martinov
T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized ther...
Michael Dougan,Glenn Dranoff,Stephanie K Dougan
Michael Dougan
Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be inhibited by immunosuppr...
Kelli A Connolly,Brittany Fitzgerald,Martina Damo et al.
Kelli A Connolly et al.
Mouse models for the study of cancer immunology provide excellent systems in which to test biological mechanisms of the immune response against cancer. Historically, these models have been designed to have different strengths based on the c...
Varun Sahu,Chao Lu
Varun Sahu
Chromatin dysfunction has been implicated in a growing number of cancers especially in children and young adults. In addition to chromatin modifying and remodeling enzymes, mutations in histone genes are linked to human cancers. Since the f...
Szu-Ying Chen,Ons Mamai,Rosemary J Akhurst
Szu-Ying Chen
Discovered over four decades ago, transforming growth factor β (TGFβ) is a potent pleiotropic cytokine that has context-dependent effects on most cell types. It acts as a tumor suppressor in some cancers and/or supports tumor progression ...
Martin W LaFleur,Arlene H Sharpe
Martin W LaFleur
Cancer immunotherapies, such as immune checkpoint blockade (ICB), have been used in a wide range of tumor types with immense clinical benefit. However, ICB does not work in all patients, and attempts to combine ICB with other immune-based t...